Stay updated on Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.4.0 to v3.4.1. No user-facing content or functionality appears affected.SummaryDifference0.1%

- Check2 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, a minor version change that does not affect study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check9 days agoChange DetectedUI changes include showing the glossary and updating QC/version-related labels on the study record; these updates do not alter trial data, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check23 days agoChange DetectedThe page shows Revision: v3.3.4 in place of Revision: v3.3.3, indicating a small internal update to the site's software.SummaryDifference0.1%

- Check44 days agoChange DetectedA dedicated Locations section was added with sites in Ohio, Tennessee, and Texas, and the previous separate location entries were removed.SummaryDifference0.5%

- Check73 days agoChange DetectedPage revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

Stay in the know with updates to Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib with Nab-Sirolimus in KRAS G12C NSCLC Clinical Trial page.